SCP1-IN-1
CAS No. 2764615-55-4
SCP1-IN-1( —— )
Catalog No. M35319 CAS No. 2764615-55-4
SCP1-IN-1 (compound SH T-62) is a potent and selective covalent inhibitor of SCP1, promoting REST degradation and reducing transcriptional activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 116 | In Stock |
|
| 5MG | 101 | In Stock |
|
| 10MG | 163 | In Stock |
|
| 25MG | 312 | In Stock |
|
| 50MG | 461 | In Stock |
|
| 100MG | 693 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSCP1-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionSCP1-IN-1 (compound SH T-62) is a potent and selective covalent inhibitor of SCP1, promoting REST degradation and reducing transcriptional activity.
-
DescriptionSCP1-IN-1 (compoundSH T-62) is a potent and selective covalent inhibitor against SCP1. SCP1-IN-1 promotes REST degradation and reduces transcriptional activity. A high level of REST protein drives the tumor growth in some glioblastoma cells. SCP1-IN-1 has the potential for the research of glioblastoma whose growth is driven by REST transcription activity.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2764615-55-4
-
Formula Weight520.5
-
Molecular FormulaC20H19F3N2O7S2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (192.12 mM; Ultrasonic )
-
SMILESFC(F)(F)Oc1ccc(cc1)S(=O)(=O)NCCOCCNC(=O)C1=Cc2ccccc2S1(=O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Amylin, amide, rat
Amylin is a peptide that displays 50% homology with calcitonin gene-related peptide (CGRP), Amylin is colocalized with somatostatin in endocrine cells of the gastric fundus. In isolated mouse stomach, amylin caused a concentration-dependent decrease in acid secretion.
-
Remimazolam
Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?
-
URB602
URB602 is a specific monoacylglycerol lipase (MGL) inhibitor, which inhibits rat brain MGL (IC50: 28±4 μM) through a noncompetitive mechanism.
Cart
sales@molnova.com